Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma

Abstract Mantle cell lymphoma (MCL) is an aggressive and largely incurable subtype of non‐Hodgkin's lymphoma. Venetoclax has demonstrated efficacy in MCL patients with relapsed or refractory disease, however response is variable and less durable than CLL. This may be the result of co‐expression of o...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaoxian Zhao, Juraj Bodo, Ruoying Chen, Lisa Durkin, Andrew J. Souers, Darren C. Phillips, Eric D. Hsi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-07-01
coleção:	eJHaem
Assuntos:	CDK9 inhibitor mantle cell lymphoma MCL‐1 venetoclax
Acesso em linha:	https://doi.org/10.1002/jha2.48
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!